PMID- 31090306
OWN - NLM
STAT- MEDLINE
DCOM- 20190815
LR  - 20190815
IS  - 1001-5302 (Print)
IS  - 1001-5302 (Linking)
VI  - 44
IP  - 7
DP  - 2019 Apr
TI  - ["Multi-component-multi-target-multi-pathway" mechanism of Kuihua Hugan Tablets 
      based on network pharmacology].
PG  - 1464-1474
LID - 10.19540/j.cnki.cjcmm.20181214.003 [doi]
AB  - To predict the targets of active ingredients of Kuihua Hugan Tablets by network 
      pharmacology, and explore the "multi-component-multi-target-multi-pathway" 
      hepatoprotective mechanism of action. First, through traditional Chinese medicine 
      systems pharmacology(TCMSP) and TCM Database@Taiwan Database, main active 
      ingredients of Kuihua Hugan Tablets were screened out based on oral 
      bioavailability(OB), drug-likeness(DL) and effective half-lives(HL). The targets 
      of active ingredients of Kuihua Hugan Tablets were predicted based on the 
      PharmMapper method. Then, the prediction was conducted by screening the target 
      genes associated with chronic hepatitis and early cirrhosis through CooLGeN and 
      GeneCards databases. Target gene functions and signal pathways were analyzed by 
      bioinformatics annotation database Metascape. Cytoscape software was used to 
      construct the Kuihua Hugan Tablets ingredient-target and 
      ingredient-target-pathway network. String database combined with Cytoscape 
      software was used to construct the networks of component-target and 
      component-target-pathway. STRING database was combined with Cytoscape software to 
      draw protein-protein interaction(PPI) network and conduct network topology 
      analysis. Finally, Systems Dock Web Site software was applied in verifying the 
      molecular docking between active ingredients and potential protein targets. A 
      total of 26 compounds and 509 potential targets were screened out from Kuihua 
      Hugan Tablets in the experiment. The results of PPI network analysis indicated 
      that albumin(ALB), insulin-like growth factor 1(IGF1), matrix 
      metalloproteinase-9(MMP9), matrix metalloproteinase-2(MMP2), non-receptor 
      tyrosine kinase proto-oncogene(SRC), estrogen receptor 1(ESR1) and cancer-signal 
      transduction-inflammation-drugs metabolism-related biological processes and 
      metabolic pathways were closely associated with the active ingredients in Kuihua 
      Hugan Tablets. The effects of Kuihua Hugan Tablets in alleviating chronic 
      hepatitis and early cirrhosis indicated the multi-component, multi-target, and 
      multi-pathway characteristics of traditional Chinese medicines, providing new 
      ideas for further research and development of Kuihua Hugan Tablets.
FAU - Shen, Hong-Bo
AU  - Shen HB
AD  - Deparment of Hepatobiliary Surgery, Quzhou People's Hospital Quzhou 324000, 
      China.
FAU - Zhou, Yi-Nong
AU  - Zhou YN
AD  - Deparment of Hepatobiliary Surgery, Quzhou People's Hospital Quzhou 324000, 
      China.
FAU - Zheng, Jie
AU  - Zheng J
AD  - Deparment of Hepatobiliary Surgery, Quzhou People's Hospital Quzhou 324000, 
      China.
FAU - Zhu, Ruo-Hai
AU  - Zhu RH
AD  - Deparment of Hepatobiliary Surgery, Quzhou People's Hospital Quzhou 324000, 
      China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhongguo Zhong Yao Za Zhi
JT  - Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese 
      materia medica
JID - 8913656
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Tablets)
MH  - Drugs, Chinese Herbal/*pharmacology
MH  - Medicine, Chinese Traditional
MH  - *Metabolic Networks and Pathways
MH  - Molecular Docking Simulation
MH  - *Protein Interaction Mapping
MH  - Tablets
OTO - NOTNLM
OT  - Kuihua Hugan Tablets
OT  - PharmMapper
OT  - chronic hepatitis and early cirrhosis
OT  - molecular docking
OT  - network pharmacology
EDAT- 2019/05/16 06:00
MHDA- 2019/08/16 06:00
CRDT- 2019/05/16 06:00
PHST- 2019/05/16 06:00 [entrez]
PHST- 2019/05/16 06:00 [pubmed]
PHST- 2019/08/16 06:00 [medline]
AID - 10.19540/j.cnki.cjcmm.20181214.003 [doi]
PST - ppublish
SO  - Zhongguo Zhong Yao Za Zhi. 2019 Apr;44(7):1464-1474. doi: 
      10.19540/j.cnki.cjcmm.20181214.003.